CGM Sensor Drift & Self-Diagnosis Patent Landscape
This field is tightly concentrated: Medtronic MiniMed and Dexcom together account for the dominant share of activity, with electrochemical impedance spectroscopy (EIS) forming the core technical approach. Annual filing volume peaked in 2020 and has since eased, signalling a maturing but still closely held IP position.
Medtronic MiniMed leads a two-player field with near-total top-tier concentration
Medtronic MiniMed holds the top position with 49 patent records, followed by Dexcom with 41. The two leaders together dominate the competitive structure; the remaining ranked applicants — I Sens Inc, the University of Virginia. Patent Foundation, and a small cluster of Chinese institutions — each hold single-digit counts.
The top five filers account for 98% of the combined total across the hundred largest filers, an exceptionally high concentration figure that signals a near-duopoly at the leading edge. The gap between second-ranked Dexcom and the third-ranked applicants is large, reinforcing a clear two-tier structure.
| # | Applicant | Patent records | Share |
|---|---|---|---|
| 1 | Medtronic MiniMed Inc | 49 | |
| 2 | Dexcom Inc | 41 | |
| 3 | I Sens Inc | 9 | |
| 4 | University of Virginia Patent Foundation | 9 | |
| 5 | Northeastern University (China) | 1 | |
| 6 | Chongqing Lianxin Zhikang Biotechnology Co., Ltd. | 1 | |
| 7 | Huashan Hospital, Fudan University | 1 |
This concentration implies that any new entrant faces well-defended IP in the core EIS-based drift-detection and self-calibration approaches. Licensing, partnership, or deliberate design-around targeting the under-served branches is likely necessary for challengers.
Filing counts for the most recent 18–24 months are subject to publication lag and will be revised upward as pending applications are published. Longer-window growth, applicant concentration, and technology-route coverage are therefore more reliable signals than the latest-year bar alone.
A 2020 peak followed by easing volume; diagnosis and informatics dominate the technology mix
The annual filing chart reveals a sharp concentration of activity around 2020, with volumes declining thereafter. The technology composition chart shows that sensor-level diagnosis (A61B) is the dominant class, with healthcare informatics and materials analysis as secondary layers.
Annual filing trend
Filing activity surged to a peak of 32 records in 2020 before stepping down through 2021–2023 and settling to low single digits in 2024–2026. Years 2024–2026 should be read as under-counted due to typical publication lag; the apparent low counts do not necessarily confirm a continuing decline.
↗ Hover for values · click a bar to ask EurekaTechnology composition
A61B (Diagnosis & surgery) is the dominant branch, reflecting the sensor-level EIS and self-calibration core of this field. A61M (Devices for body fluids) and G16H (Healthcare informatics) are the next largest classes, indicating that system-level and software-layer protection is a secondary but meaningful focus. Lower-share branches — G01N, G06K, G06N, H04L, and H04M — represent thinner coverage in materials testing, AI models, and communications.
↗ Hover for values · click a bar to ask EurekaHighly cited patent families surfaced by the query
Citation-heavy patent families returned by the query. Use this section as citation context, not as a curated list of the most topic-specific patents.
System, method and computer readable medium for co…
A system or method for compressing continuous glucose monitor (CGM) data for a subject and/or a technician, clinician, or for use with an interventional device. The system or method configures the CGM data to allow the subject, technician, clinician, or interventional device to take a physical action in response to receiving a transmission to improve the… (excerpt from the patent abstract)
| # | Patent | Citations |
|---|---|---|
| 1 | Use of electrochemical impedance spectroscopy (EIS… | 56 |
| 2 | Use of electrochemical impedance spectroscopy (EIS… | 44 |
| 3 | Methods for continuous glucose monitoring | 40 |
| 4 | Sensor systems, devices, and methods for continuou… | 28 |
| 5 | Multi-state engagement with continuous glucose mon… | 21 |
| 6 | 电化学阻抗谱(EIS)在连续葡萄糖监测中的使用 | 18 |
| 7 | Use of electrochemical impedance spectroscopy (EIS… | 17 |
| 8 | Glucose measurement predictions using stacked mach… | 13 |
Ranked by total forward citations. Citation counts favour older and broadly cited patent families, and broad or adjacent patents may appear when they match the search scope. Treat this section as citation context, not as a curated list of the most topic-specific patents. Some patent titles may be shown in their original, non-English language where an accurate translation could not be guaranteed.
What the competitive structure means for R&D strategy
The combination of high concentration, a peaked filing curve, and a dominant diagnostic method (EIS) shapes the strategic options available to incumbents and new entrants alike.
Field is in decline from a 2020 peak
The lifecycle stage is assessed as Decline, with annual filings easing back from the 2020 peak of 32 records. The core EIS-based drift-detection approach appears to have reached saturation in primary claims. R&D investment is most defensible in adjacent technical areas not yet claimed by the two leaders.
Past-peak · 2020Near-duopoly with a wide gap to tier three
Medtronic MiniMed and Dexcom collectively dominate the top of the ranking. The top five filers account for 98% of the combined total across the hundred largest filers. For new entrants, the cost of challenging core positions is high; the more tractable path is differentiated coverage in informatics, AI, or materials characterisation.
Top-2 dominantMinimal co-filing; one academic pairing observed
The only co-filing relationship in evidence is between Huashan Hospital of Fudan University and Northeastern University (China), with one joint record. No collaboration between the two commercial leaders or between commercial and academic entities is recorded. The ecosystem is essentially siloed, which may leave academic-clinical consortia as an underused channel for differentiated filings.
Low ecosystem densityUS-centric protection; limited Asia-Pacific reach
The United States accounts for 60 patent records — the single dominant jurisdiction. Europe (EPO) follows with 14, then Australia with 10 and Canada with 9. China holds only 4 records despite local applicants being present, suggesting that the two US leaders have not prioritised Chinese prosecution in this specific sub-field. This creates a jurisdictional gap that regional entrants could exploit.
US-primary · China thinGo beyond the landscape: Eureka’s TRIZ Solution agent breaks down an R&D problem and returns patented concept solutions, each with a technical approach and cited patent & literature evidence.
| Applicant | Collaborator | Co-filings |
|---|---|---|
| Huashan Hospital, Fudan University | Northeastern University (China) | 1 |
Co-filing pairs, ranked by the number of jointly-filed patent families.
Medtronic MiniMed anchors EIS and hardware; Dexcom emphasises informatics and healthcare data
The two leaders pursue distinct but complementary technical emphases, making direct design-around moderately difficult. Both show divergent recent momentum.
Medtronic MiniMed Inc
Ranked first with 49 patent records, Medtronic MiniMed’s portfolio is concentrated in A61B 5 (core diagnosis and sensor), A61M 5 (drug-delivery and fluid devices), and G01N 27 (electrochemical materials analysis) — reflecting deep hardware and EIS methodology coverage. Recent momentum is assessed as a new entrant pattern in the most recent window (7 recent records), suggesting continued but measured prosecution activity.
patent records: 49Dexcom Inc
Ranked second with 41 patent records, Dexcom’s emphasis is on A61B 5 (sensor diagnosis) combined with G16H 40 and G16H 50 (healthcare informatics — management and decision-support), indicating a stronger software and data-layer strategy relative to Medtronic MiniMed. However, recent momentum shows a sharp decline (assessed at –97% vs prior period), suggesting that near-term new filings in this sub-field from Dexcom are limited.
patent records: 41| Applicant | Recent (3 yrs) | Trend |
|---|---|---|
| Medtronic MiniMed Inc | 7 | ▲ new entrant |
| Dexcom Inc | 1 | ▼ -97% |
| University of Virginia Patent Foundation | 5 | ▲ new entrant |
| Chongqing Lianxin Zhikang Biotechnology Co., Ltd. | 1 | ▲ new entrant |
Under-served branches in AI, materials testing, and communications
Several IPC branches at the margins of this corpus carry low record counts relative to the dominant A61B class. These represent observations of relative sparsity; where plausible technical value and a realistic entry path exist, they may warrant closer investigation.
G06N · AI and machine-learning models
With only 7 records and a 3% share, the AI-model branch is sparse despite machine-learning approaches being widely applicable to sensor-drift prediction and anomaly detection. The most-cited patent on glucose measurement predictions using stacked machine learning confirms technical relevance. An entrant with proprietary training data or novel model architectures could build differentiated claims here without directly confronting the EIS-centred core.
Search this in Eureka →G01N · Electrochemical and materials analysis
G01N holds 17 records (7% share) and is the largest of the sparse branches, yet it sits at the heart of the EIS methodology that dominates top-cited patents. The sparsity relative to A61B suggests that materials-characterisation claims — such as novel electrode coatings or electrolyte formulations that reduce drift at source — are less fully claimed. For a materials-science-oriented entrant, upstream chemistry and sensor-surface protection could be a defensible entry point.
Search this in Eureka →How leaders differ across technology routes
Route coverage across the main technology branches in the current evidence set.
| Player | A61B 5 · Diagnosis & surgery | A61M 5 · Devices for body fluids | G16H 40 · Healthcare informatics | G16H 50 · Healthcare informatics | G16H 10 · Healthcare informatics |
|---|---|---|---|---|---|
| Dexcom Inc | Strong · 41 | Absent | Moderate · 18 | Moderate · 14 | Moderate · 12 |
| Medtronic MiniMed Inc | Strong · 49 | Strong · 27 | Absent | Absent | Absent |
| University of Virginia Patent Foundation | Strong · 9 | Strong · 7 | Strong · 7 | Strong · 7 | Strong · 7 |
| I Sens Inc | Strong · 9 | Absent | Absent | Absent | Absent |
| Northeastern University (China) | Strong · 1 | Absent | Absent | Absent | Absent |
| Huashan Hospital, Fudan University | Strong · 1 | Absent | Absent | Absent | Absent |
| Chongqing Lianxin Zhikang Biotechnology Co., Ltd. | Strong · 1 | Absent | Absent | Absent | Absent |
Frequently asked questions
The corpus contains 73 patent families in scope across this topic globally.
Medtronic MiniMed Inc leads with 49 patent records, followed by Dexcom Inc with 41. I Sens Inc and the University of Virginia Patent Foundation each hold 9 records; the remaining filers hold single-digit counts.
Electrochemical impedance spectroscopy (EIS) is the dominant technical approach, appearing across the most-cited titles in the corpus. Machine-learning-based glucose measurement prediction is a secondary but cited direction.
The United States is the primary jurisdiction with 60 patent records. Europe (EPO) follows with 14, then Australia with 10, Canada with 9, and WIPO (PCT) with 7. China holds only 4 records, which is relatively thin given the local applicants present in the corpus.
Annual filings peaked in 2020 at 32 records and have since eased, consistent with a decline lifecycle stage. Recent-year counts (2024–2026) are subject to publication lag and will increase as pending applications publish, so the current low figures should not be read as final.
The sparsest adjacent branches relative to the A61B core are G06N (AI and machine-learning models, 7 records), G06K (data recognition, 8 records), H04L and H04M (communications, 6 records each), and G01N (materials analysis, 17 records). The AI-model and upstream materials-characterisation directions have plausible technical relevance and thinner incumbent coverage.
Built on Patsnap Open Platform
This report’s underlying patent dataset — filings, assignees, technology clusters — is open for developers via MCP and REST API. Free to start, 10,000 credits, no credit card required.
Disclaimer. This page is generated from Patsnap Eureka data drawn from a limited snapshot of global patent and scientific-literature records, and is provided for general information and reference only.
Patent data carries inherent limitations: recent filings (typically the most recent 18–24 months) are under-counted due to standard publication lag; counts may be reported at either a patent-family or a patent-record basis and are not always directly comparable; classification, applicant-name, and citation data may contain errors, duplicates, or omissions; and the underlying search query defines and constrains the scope shown. As a result, the analysis may be incomplete or inaccurate and may not reflect the full technology landscape.
Nothing on this page constitutes an exhaustive prior-art, novelty, freedom-to-operate, or validity search, nor does it constitute legal, financial, investment, or professional advice, and it should not be relied upon as such. Any patent, commercial, or strategic decision should be verified independently and reviewed with qualified patent, legal, and domain professionals. Patsnap makes no warranties, express or implied, as to the accuracy, completeness, or fitness for any particular purpose of the information presented.